 "Rossari Biotech IPO subscribed 79.4 times, generates bids worth Rs 27K cr")
Rossari Biotech has received 79.4 times the demand of shares on offer in its initial public offering (IPO), on Wednesday, which is the last day of the issue. The institutional investor portion of the IPO was subscribed more than 85 times, the wealthy investor portion subscribed 240 times, and the retail investor portion garnered 7.2 times subscription.
The IPO saw over 600,000 application and generated bids worth over Rs 27,000 crore.
Given the high demand, the IPO is likely to be priced at the top-end of the price band of Rs 423-425 per share. At the top end, the company commands a market capitalisation of Rs 2,207 crore on post-IPO basis.
One subscription. Two world-class reads.
Already subscribed? Log in
Subscribe to read the full story →*Subscribe to Business Standard digital and get complimentary access to The New York Times
Smart Quarterly
₹900
3 Months
₹300/Month
SAVE 25%
Smart Essential
₹2,700
1 Year
₹225/Month
SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months
Super Saver
₹3,900
2 Years
₹162/Month
Subscribe
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors
Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share
Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor
Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements
Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
SAVE 25%